BCL2L1 and neuroblastoma: Previous studies have mainly been performed with the BCL-2/BCL-XL inhibitors ABT-737 and ABT-263, and the sensitivity of neuroblastoma cells to these BH3-mimetics has largely been attributed to an inhibition of BCL-2 rather than BCL-XL.